Globalize Your Company's Mental Health Initiatives
If your global mental health programs aren't gaining traction, factors beyond just stigma may be standing in the way. To create initiatives that resonate across geographic regions, ethnic backgrounds, and value systems, rethink your approach. Here's how to overcome common pitfalls and deliver real results.
Question your assumptions about culture. Don't jump to conclusions when initiatives fall flat. Low participation might not point to cultural resistance, but to a lack of trust. Before cutting programs, investigate underlying issues. Prioritize confidentiality, train managers on privacy, and foster trust. When people feel safe, they're more likely to engage.
Engage with creativity, not just information. If mental health stigma exists, don't fight it head-on—find indirect ways to spark dialogue. Use small-group sessions, hands-on activities, or family-centered programs to open conversations naturally. Make your initiatives feel relevant and accessible, not like another corporate checkbox.
Plan strategically from the start. Avoid rolling out generic, one-size-fits-all solutions. Understand the specific needs of different employee groups, from awareness levels to cultural attitudes. Segment your programs accordingly and provide managers with tailored support so they can lead confidently. When programs meet people where they are, change becomes possible.
Source: This tip is adapted from 'Making Mental Health Programs Work at Multinational Companies,' by Enoch Li.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Health Line
11 minutes ago
- Health Line
What to Know About High Functioning Schizophrenia
When a person's schizophrenia symptoms do not appear to interfere with their daily life, their condition may be referred to as high functioning schizophrenia. But this is not an official diagnosis. Schizophrenia is a complex and varied psychiatric disorder that affects each person differently. Some people have relatively mild symptoms that come and go. Others experience more severe, persistent symptoms that interfere with their daily lives. When a person with schizophrenia is able to live a mostly independent life, hold a job, and maintain relationships, their condition is often referred to as 'high functioning.' Language matters The term 'high functioning' doesn't have a clear medical definition. Some clinicians use it to refer to people who require a lower level of assistance for daily activities. But terms like 'high functioning' and 'low functioning' don't account for people's unique life circumstances, abilities, and strengths. It's best to avoid using this kind of language outside of a conversation with your healthcare professional. What is high functioning schizophrenia? High functioning schizophrenia is a term used when people with schizophrenia are able to function well in daily life despite their diagnosis. They may have milder symptoms, or they may have developed good coping mechanisms despite having more severe symptoms. It's important to note that 'high functioning' is a subjective term and not a clinical diagnosis. And the label doesn't necessarily reflect the severity of a person's symptoms. People with high functioning schizophrenia may still experience significant challenges and need continuous treatment and support. A person's level of functioning can be influenced by a range of factors, including: Symptom severity: People with fewer or less severe symptoms may be able to function better in daily life than those with more severe symptoms. Treatment response: Those who get timely, appropriate treatment are more likely to maintain good functioning. Research from 2020 suggests that early intervention may be linked to better long-term outcomes. Personal coping strategies: Some people develop strong coping strategies that allow them to effectively manage their symptoms and prevent those symptoms from having a major effect on their daily life. Strong support network: Those with very supportive family and friends may be able to function better in daily life than those who don't have this support. Lack of other mental or physical health conditions: Many people with schizophrenia have other mental or physical health conditions that make it more difficult to function in daily life. People who don't have another condition may appear higher functioning. Symptoms of high functioning schizophrenia Any person with schizophrenia, whether it's considered 'high' or low' functioning, can experience the same types of symptoms. Schizophrenia symptoms are divided into positive, negative, and cognitive symptoms. Positive symptoms are those that 'add' to your personality (in other words, they weren't there before the condition). These symptoms include those of psychosis, such as: hallucinations delusions disorganized thoughts and speech atypical motor behavior (e.g., catatonia) Negative symptoms 'take away' from your personality and involve five key areas: alogia (reduction in the number of words spoken) anhedonia (reduced experience of pleasure) asociality (reduced social activity) avolition (reduced goal-directed activity, due to decreased motivation) blunted affect (difficulty expressing emotions, such as diminished facial expressions) Cognitive symptoms may include issues with: focus and attention span working memory executive functioning The negative symptoms of schizophrenia are often more challenging to treat than the positive symptoms. For some people with schizophrenia, these negative symptoms persist, even when positive symptoms are well managed. Research from 2020 suggests that negative symptoms are associated with poorer outlook and long-term disability. While many people with high functioning schizophrenia do have negative symptoms, these symptoms may be less severe. Diagnosing high functioning schizophrenia In the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. text revision (DSM-5-TR), schizophrenia is now listed as a spectrum disorder. This more accurately represents the condition's wide range of symptoms that can change over time. It's important to note that high functioning schizophrenia is not a clinical diagnosis. So, whether a person exhibits a higher or lower level of functioning, they still have to meet the same diagnostic criteria. A diagnosis of schizophrenia must include at least two of the following symptoms, with one of these symptoms being among the first three: delusions hallucinations disorganized speech severely disorganized or catatonic behavior negative symptoms The symptoms must occur frequently for at least 1 month, with some symptoms lasting for more than 6 months. In addition, you'll need to have experienced reduced functioning in one or more important areas of life, such as personal relationships, work, or self-care. Treating schizophrenia Schizophrenia is typically treated with antipsychotic medication as well as various types of therapies and skills training. Schizophrenia may be treated with the following: Atypical antipsychotics: Atypical, or second-generation, antipsychotics are the first-line treatment for schizophrenia. These medications lower dopamine levels in the brain, which helps target symptoms of psychosis. Cognitive behavioral therapy (CBT): CBT helps people with schizophrenia identify and fix unhelpful thought processes and behaviors. Social skills training: Social skills interventions help people with schizophrenia learn social and independent living skills. These may include classes covering interpersonal skills and medication management. Cognitive remediation: This intervention focuses on skills such as attention, memory, and flexible thinking. Social cognition training: This intervention targets skills such as social perception (understanding social cues or body language), emotion perception (identifying others' emotions), and theory of mind (identifying and understanding another person's mental state). Some people with high functioning schizophrenia may have achieved symptom remission after responding well to treatment. Symptom remission means that your symptoms are mild enough to not significantly interfere with your life. Research from 2018 suggests that symptom remission is possible in 20% to 60% of people with schizophrenia, but this depends on many complex factors.
Associated Press
an hour ago
- Associated Press
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Files ANDA for Preservative-Free IV Ketamine
IBN published this article, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - June 5, 2025 ( NEWMEDIAWIRE ) - NRx Pharmaceuticals (NASDAQ: NRXP), has submitted an Abbreviated New Drug Application (ANDA) to the FDA for NRX-100, its preservative-free intravenous ketamine formulation aimed at approved indications such as anesthesia and pain management. With the U.S. ketamine market valued at $750 million and global demand projected to reach $3.35 billion by 2034, the company is seeking priority review amid an ongoing national shortage. NRx also plans to petition the FDA to mandate preservative-free ketamine formulations, citing safety concerns over benzethonium chloride. This filing complements its broader strategy to expand ketamine's label to include treatment for suicidal depression, backed by clinical data from more than 1,000 patients. To view the full press release, visit About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI. NRx has recently initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality. NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: The latest news and updates relating to NRXP are available in the company's newsroom at Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading 'Risk Factors' discussed under the caption 'Item 1A. Risk Factors' in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption 'Item 1A. Risk Factors' in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law. About IBN IBN is a cutting-edge communications and digital engagement platform providing tailored Platform Solutions for select private and public companies. Over the course of 19+ years, IBN has introduced over 70 investor facing brands to the investment public and amassed a collective audience of millions of social media followers. These distinctive investor brands amplify recognition and reach as well as help fulfill the unique needs of our rapidly growing and diverse base of client-partners. IBN will continue to expand our branded network of influential properties as well as leverage the energy and experience of our team of professionals to best serve our clients. IBN's Platform Solutions provide access to: (1) our Dynamic Brand Portfolio (DBP) through 70+ investor facing brands; (2) article and editorial syndication to 5,000+ news outlets; (3) full-scale distribution to a growing Social Media Network (SMN) ; (4) a network of wire solutions via InvestorWire to effectively reach target markets and demographics; (5) Press Release Enhancement to ensure accuracy and impact; (6) a full array of corporate communications solutions; and (7) total news coverage solutions. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: Media Contact IBN Los Angeles, California 310.299.1717 Office [email protected] View the original release on
Forbes
an hour ago
- Forbes
Late ADHD Diagnoses In Women Are Shaping A New Leadership Model
For many high-achieving women, leadership has meant working twice as hard to prove they belong in the room. But for a growing number, there's another layer to the story, and it was hidden in plain sight for years. Women are being diagnosed with ADHD not in childhood but in midlife, after decades of navigating leadership roles with an invisible challenge. Between 2020 and 2022, the incidence of ADHD diagnoses among women aged 23–29 and 30–49 nearly doubled. This trend highlights the growing awareness that ADHD often presents differently in women and is frequently diagnosed later in life compared to men, as reported by Epic Research. Attention-Deficit/Hyperactivity Disorder has long been seen as a childhood condition, typically associated with hyperactive boys disrupting classrooms. But women—especially those in leadership—often don't fit the mold. They may present as driven, organized and articulate. Behind the scenes, though, many are masking executive dysfunction, working long hours to compensate for distractibility and feeling constant internal overwhelm. 'Women with ADHD tend to display more difficulties with attention compared to men,' states Anne Castley Burdzy, PhD., founder of BeWell Psychology. 'Women in leadership roles might find themselves task-switching more frequently or maybe more easily distracted compared to their male counterparts.' Women are significantly more likely to be diagnosed later in life during career transitions or hormonal changes. For female leaders, that late diagnosis sparks both relief and regret. Once diagnosed, many women experience a seismic shift—not in capability, but in self-compassion. Rather than framing their struggles as personal failings, they begin to reframe them as neurological differences. That lens allows for greater empathy toward themselves and, in many cases, their teams. It also transforms how they lead. 'You are not broken, lazy or unqualified; your brain just works differently, and that's not a flaw, it's a feature,' Summer Jelinek, a keynote speaker and leadership trainer, advises emerging leaders. 'Build systems that work for your brain, not against it.' Jelinek discovered her ADHD during her Ph.D. program, adding to her earlier autism diagnosis. This dual realization, known as AuDHD, provided clarity on her past corporate experiences and leadership challenges. 'That internal tug-of-war confused me and definitely confused my leaders,' she explains. 'I spent a massive amount of energy trying to hide both, constantly managing how I showed up so I didn't seem too intense, too much or too sensitive.' Post-diagnosis, Jelinek wears her neurodivergence on her sleeve, creating a safe space for others; she leads from a place of authenticity rather than performance. She emphasizes the importance of building systems that align with one's unique cognitive patterns. For Pubali Sen, head of ChomChomTech and serving as AI/ML Solutions at Google, the realization of her ADHD at age 31 was a transformative moment. 'My 'aha!' moment was less of a gentle dawn and more of a full-blown fireworks display,' she recounts. This diagnosis provided clarity on her past behaviors and led her to develop structured systems to manage her responsibilities effectively. Sen describes her ADHD as a catalyst for innovation. 'My ADHD brain is like having a super-fast internet connection with about 50 tabs open simultaneously,' she explains. Embracing her neurodivergence, she advocates for inclusive leadership that values diverse cognitive styles. At ChomChomTech, Sen channels her experiences into creating AI-powered tools that support the emotional regulation and imaginative skills of neurodivergent children. Her leadership exemplifies how understanding and embracing one's cognitive profile leads to more effective and empathetic leadership. Sandra Bean, founder of St. Pete Girl Boss, was diagnosed at 40, which led to a transformation in her leadership approach from self-criticism to self-compassion. 'I realized it wasn't that I wasn't trying hard enough,' she reflects. 'I needed extra support.' From this insight, she implements supportive systems such as time blocking. Bean's ADHD has enhanced her networking and negotiation skills. However, she acknowledges challenges such as rejection sensitivity and time blindness, which she addresses through strategies like body doubling. She has another person present while working on a task, either in person or virtually, to stay focused and motivated. This person doesn't actively help with the task itself; they are there to act as an accountability partner. Bean advocates for leadership that values cognitive flexibility. 'We don't do things the 'normal' way; we do them the necessary way,' she asserts, emphasizing the importance of creating spaces where diverse minds can thrive. Leadership doesn't require perfect focus or linear thinking. By embracing ADHD as a strength, these women are creating new models for what effective, empathetic leadership can look like. The future of leadership is not quieter or neater. It is more human and raw. Key characteristics of this emerging ADHD-informed leadership model include: Neuro-inclusive workplaces are the future of organizations; it's about redesigning meetings to reduce cognitive overload and offering more flexible workflows while being transparent about how neurodivergent leaders' brains function. The more these leaders share their stories, the more they're paving the way for others, especially younger employees who may be struggling silently. The diagnosis isn't a weakness. For many, it's a key to unlocking their full leadership potential. 'Specific accommodations for women with ADHD include providing clear expectations, allowing ample time for tasks with effective prompts and breaking larger tasks into smaller, manageable parts,' Dr. Castley Burdzy concludes. 'Creating a workplace environment that is healthy and supportive gives leaders a space to advocate and implement strategies that they find helpful.'
